WO2008090570A1 - Nouveaux antimicrobiens - Google Patents
Nouveaux antimicrobiens Download PDFInfo
- Publication number
- WO2008090570A1 WO2008090570A1 PCT/IN2008/000047 IN2008000047W WO2008090570A1 WO 2008090570 A1 WO2008090570 A1 WO 2008090570A1 IN 2008000047 W IN2008000047 W IN 2008000047W WO 2008090570 A1 WO2008090570 A1 WO 2008090570A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oxo
- phenyl
- oxazolidin
- ylmethyl
- compound
- Prior art date
Links
- 239000004599 antimicrobial Substances 0.000 title abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 410
- 238000000034 method Methods 0.000 claims abstract description 36
- 239000000651 prodrug Substances 0.000 claims abstract description 22
- 229940002612 prodrug Drugs 0.000 claims abstract description 22
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- 239000002207 metabolite Substances 0.000 claims abstract description 19
- 239000012453 solvate Substances 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 230000008569 process Effects 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 8
- 241001112696 Clostridia Species 0.000 claims abstract description 5
- 241000194033 Enterococcus Species 0.000 claims abstract description 5
- 241000606768 Haemophilus influenzae Species 0.000 claims abstract description 5
- 241000588621 Moraxella Species 0.000 claims abstract description 5
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims abstract description 5
- 241000191940 Staphylococcus Species 0.000 claims abstract description 5
- 241000194017 Streptococcus Species 0.000 claims abstract description 5
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims description 72
- -1 aryloxythiocarbonyl Chemical group 0.000 claims description 44
- 125000001072 heteroaryl group Chemical group 0.000 claims description 39
- 125000003118 aryl group Chemical group 0.000 claims description 35
- 238000006243 chemical reaction Methods 0.000 claims description 31
- 125000000217 alkyl group Chemical group 0.000 claims description 29
- 125000000623 heterocyclic group Chemical group 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 23
- 125000001424 substituent group Chemical group 0.000 claims description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims description 21
- 239000001257 hydrogen Substances 0.000 claims description 21
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 19
- 229910052736 halogen Inorganic materials 0.000 claims description 17
- 150000002367 halogens Chemical class 0.000 claims description 17
- 125000003342 alkenyl group Chemical group 0.000 claims description 16
- 125000000304 alkynyl group Chemical group 0.000 claims description 15
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 14
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 14
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 150000002431 hydrogen Chemical group 0.000 claims description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
- 125000002252 acyl group Chemical group 0.000 claims description 11
- 150000001412 amines Chemical class 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 208000035143 Bacterial infection Diseases 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 9
- 239000002585 base Substances 0.000 claims description 9
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 8
- 230000000844 anti-bacterial effect Effects 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 125000003441 thioacyl group Chemical group 0.000 claims description 7
- 229910052720 vanadium Inorganic materials 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 238000011321 prophylaxis Methods 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 5
- 125000004685 alkoxythiocarbonyl group Chemical group 0.000 claims description 5
- 125000006239 protecting group Chemical group 0.000 claims description 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 5
- 125000006651 (C3-C20) cycloalkyl group Chemical group 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 3
- 125000005090 alkenylcarbonyl group Chemical group 0.000 claims description 3
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 claims description 3
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- HRKQOINLCJTGBK-UHFFFAOYSA-N dihydroxidosulfur Chemical compound OSO HRKQOINLCJTGBK-UHFFFAOYSA-N 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 claims description 3
- 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 claims description 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 3
- PFBSKKDDNYQKQR-UHFFFAOYSA-N n-azido-1-sulfanylidenemethanimine Chemical compound [N-]=[N+]=NN=C=S PFBSKKDDNYQKQR-UHFFFAOYSA-N 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- 239000011574 phosphorus Substances 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- YKOWBJJOJNGCAD-SHYZEUOFSA-N [(2r,3s,5r)-3-hydroxy-5-[4-(hydroxyamino)-2-oxopyrimidin-1-yl]oxolan-2-yl]methyl dihydrogen phosphate Chemical compound O=C1N=C(NO)C=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 YKOWBJJOJNGCAD-SHYZEUOFSA-N 0.000 claims description 2
- 125000004171 alkoxy aryl group Chemical group 0.000 claims description 2
- 239000003899 bactericide agent Substances 0.000 claims description 2
- 239000012351 deprotecting agent Substances 0.000 claims description 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 claims description 2
- 125000005027 hydroxyaryl group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- YLNSNVGRSIOCEU-UHFFFAOYSA-N oxiran-2-ylmethyl butanoate Chemical compound CCCC(=O)OCC1CO1 YLNSNVGRSIOCEU-UHFFFAOYSA-N 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- VNVALNOVDDOJNH-UHFFFAOYSA-N 2-[4-[(6-fluoro-1,3-benzothiazol-2-yl)oxy]-2-hydroxyphenyl]-N-methylacetamide Chemical compound FC1=CC2=C(N=C(S2)OC2=CC(=C(C=C2)CC(=O)NC)O)C=C1 VNVALNOVDDOJNH-UHFFFAOYSA-N 0.000 claims 1
- 150000004982 aromatic amines Chemical class 0.000 claims 1
- 238000006264 debenzylation reaction Methods 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- DKWQRTOMZSJFET-SFHVURJKSA-N n-[[(5s)-3-[4-[4-(cyclopentylmethoxy)-4-oxo-1,4$l^{5}-azaphosphinan-1-yl]-3,5-difluorophenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC(F)=C1N1CCP(=O)(OCC2CCCC2)CC1 DKWQRTOMZSJFET-SFHVURJKSA-N 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- NCTCGHLIHJJIBK-UHFFFAOYSA-N 3-phenyl-1,3-oxazolidin-2-one Chemical class O=C1OCCN1C1=CC=CC=C1 NCTCGHLIHJJIBK-UHFFFAOYSA-N 0.000 abstract description 6
- 244000000058 gram-negative pathogen Species 0.000 abstract description 6
- 244000000059 gram-positive pathogen Species 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 108
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 68
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 63
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 52
- 239000011541 reaction mixture Substances 0.000 description 44
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 42
- 239000011734 sodium Substances 0.000 description 37
- 239000002904 solvent Substances 0.000 description 37
- 239000000243 solution Substances 0.000 description 36
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 33
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 30
- 238000004440 column chromatography Methods 0.000 description 28
- 238000005160 1H NMR spectroscopy Methods 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 20
- 239000012044 organic layer Substances 0.000 description 20
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 20
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 19
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 239000012043 crude product Substances 0.000 description 16
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 125000000753 cycloalkyl group Chemical group 0.000 description 14
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 239000012267 brine Substances 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- FAKKOTXPHDKJRH-UHFFFAOYSA-N azaphosphinane Chemical compound C1CCPNC1 FAKKOTXPHDKJRH-UHFFFAOYSA-N 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 10
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- 239000003242 anti bacterial agent Substances 0.000 description 10
- 229910000027 potassium carbonate Inorganic materials 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 229960004132 diethyl ether Drugs 0.000 description 9
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 229960003907 linezolid Drugs 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940098779 methanesulfonic acid Drugs 0.000 description 5
- 125000004043 oxo group Chemical group O=* 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 0 CCCc(c(NCCP(*)=*)c1*)c(CC)c(N)c1[U] Chemical compound CCCc(c(NCCP(*)=*)c1*)c(CC)c(N)c1[U] 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 239000007818 Grignard reagent Substances 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 150000004795 grignard reagents Chemical class 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- RUBQQRMAWLSCCJ-UHFFFAOYSA-N 1,2-difluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C(F)=C1 RUBQQRMAWLSCCJ-UHFFFAOYSA-N 0.000 description 2
- NUJCDWBPIOHLCW-UHFFFAOYSA-N 1-bis(ethenyl)phosphoryloxyethane Chemical compound CCOP(=O)(C=C)C=C NUJCDWBPIOHLCW-UHFFFAOYSA-N 0.000 description 2
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 2
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000004181 carboxyalkyl group Chemical group 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- SJYNFBVQFBRSIB-UHFFFAOYSA-N norbornadiene Chemical compound C1=CC2C=CC1C2 SJYNFBVQFBRSIB-UHFFFAOYSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 229910052707 ruthenium Inorganic materials 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- SCVRYANQGJLRQS-OAHLLOKOSA-N (5r)-3-[3,5-difluoro-4-(4-oxo-4-phenyl-1,4$l^{5}-azaphosphinan-1-yl)phenyl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one Chemical compound O=C1O[C@@H](CO)CN1C(C=C1F)=CC(F)=C1N1CCP(=O)(C=2C=CC=CC=2)CC1 SCVRYANQGJLRQS-OAHLLOKOSA-N 0.000 description 1
- PTTUMBGORBMNBN-UHFFFAOYSA-N 1,2,3-trifluoro-5-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(F)=C(F)C(F)=C1 PTTUMBGORBMNBN-UHFFFAOYSA-N 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- BBXDMCQDLOCXRA-UHFFFAOYSA-N 1-(chloromethyl)-2-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1CCl BBXDMCQDLOCXRA-UHFFFAOYSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- CSNMVMCYOGMCIJ-UHFFFAOYSA-N 4-(1-bicyclo[3.1.0]hexanyl)-3-phenyl-1,3-oxazolidin-2-one Chemical class O=C1OCC(C23C(C2)CCC3)N1C1=CC=CC=C1 CSNMVMCYOGMCIJ-UHFFFAOYSA-N 0.000 description 1
- RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical compound OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical group C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000037041 Community-Acquired Infections Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- YLNSNVGRSIOCEU-ZCFIWIBFSA-N [(2r)-oxiran-2-yl]methyl butanoate Chemical compound CCCC(=O)OC[C@H]1CO1 YLNSNVGRSIOCEU-ZCFIWIBFSA-N 0.000 description 1
- XAKBSHICSHRJCL-UHFFFAOYSA-N [CH2]C(=O)C1=CC=CC=C1 Chemical group [CH2]C(=O)C1=CC=CC=C1 XAKBSHICSHRJCL-UHFFFAOYSA-N 0.000 description 1
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 description 1
- 125000001539 acetonyl group Chemical group [H]C([H])([H])C(=O)C([H])([H])* 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000002814 agar dilution Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 150000003939 benzylamines Chemical class 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- MQYVNIBIZOJEGZ-UHFFFAOYSA-N bicyclo[2.2.1]hepta-2,4-diene Chemical compound C1C2CC=C1C=C2 MQYVNIBIZOJEGZ-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- LEVVKXBDNCAQHL-UHFFFAOYSA-N bis(ethenyl)phosphinic acid Chemical compound C=CP(=O)(O)C=C LEVVKXBDNCAQHL-UHFFFAOYSA-N 0.000 description 1
- QJPDCMIFPPRCFH-UHFFFAOYSA-N bis(ethenyl)phosphorylbenzene Chemical compound C=CP(=O)(C=C)C1=CC=CC=C1 QJPDCMIFPPRCFH-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- UCNOWPFANCAMCE-UHFFFAOYSA-N bromo(trimethyl)silane;dichloromethane Chemical compound ClCCl.C[Si](C)(C)Br UCNOWPFANCAMCE-UHFFFAOYSA-N 0.000 description 1
- 238000002815 broth microdilution Methods 0.000 description 1
- NRDQFWXVTPZZAZ-UHFFFAOYSA-N butyl carbonochloridate Chemical group CCCCOC(Cl)=O NRDQFWXVTPZZAZ-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- ISQVBYGGNVVVHB-UHFFFAOYSA-N cyclopentylmethanol Chemical compound OCC1CCCC1 ISQVBYGGNVVVHB-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 125000004598 dihydrobenzofuryl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 208000027136 gram-positive bacterial infections Diseases 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 239000003041 laboratory chemical Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- AGJSNMGHAVDLRQ-HUUJSLGLSA-N methyl (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,3-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(=O)OC)CC1=CC=C(O)C(C)=C1C AGJSNMGHAVDLRQ-HUUJSLGLSA-N 0.000 description 1
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical class COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- TVALQFKVUKJSJL-IBGZPJMESA-N n-[[(5s)-3-[3,5-difluoro-4-(4-oxo-4-quinolin-8-yloxy-1,4$l^{5}-azaphosphinan-1-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC(F)=C1N1CCP(=O)(OC=2C3=NC=CC=C3C=CC=2)CC1 TVALQFKVUKJSJL-IBGZPJMESA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 150000005181 nitrobenzenes Chemical class 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000003431 oxalo group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 150000002959 penams Chemical class 0.000 description 1
- 150000002961 penems Chemical class 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical group O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- LJZPPWWHKPGCHS-UHFFFAOYSA-N propargyl chloride Chemical compound ClCC#C LJZPPWWHKPGCHS-UHFFFAOYSA-N 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229940061740 zyvox Drugs 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
Definitions
- the present invention relates to novel phenyl oxazolidinone compounds of formula I or their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof.
- the invention also relates to the processes for the synthesis of novel compounds of formula I or their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof.
- the present invention also provides pharmaceutical compositions comprising novel compounds of formula I and methods of using them.
- the compounds of the present invention are useful as antimicrobial agents, effective against a number of aerobic and/or anaerobic Gram positive and/or Gram negative pathogens such as multi drug resistant Staphylococcus spp., Streptococcus spp., Enterococcus spp., Bacterioides spp., Clostridia spp., H. influenza, Moraxella Spp., as well as acid-fast organisms such as Mycobacterium tuberculosis and the like.
- aerobic and/or anaerobic Gram positive and/or Gram negative pathogens such as multi drug resistant Staphylococcus spp., Streptococcus spp., Enterococcus spp., Bacterioides spp., Clostridia spp., H. influenza, Moraxella Spp., as well as acid-fast organisms such as Mycobacterium tuberculosis and the like.
- MRSA Methicillin Resistant Staphylococcus aureus
- VRE Vancomycin Resistant Enterococci
- GISA Glycopeptide Resistant Staphylococcus aureus
- Oxazolidinones are a class of antibacterial agents with a unique mechanism of inhibiting bacterial protein synthesis. They inhibit the formation of ribosomal initiation complex involving 30S and 50S ribosoines leading to prevention of initiation complex formation at the stage of protein synthesis. Due to their unique mechanism of action, these compounds are active against pathogens resistant to other clinically useful antibiotics.
- Several patent publications disclose oxazolidinones as antimicrobial agents.
- WO 07/114326 US 07/0155798, WO 07/040326, WO 07/095784, WO 07/000432, WO 07/004037 and WO 07/093904 disclose phenyl oxazolidinone derivatives to be useful as antibacterial agents.
- WO 06/109056, WO 06/035283, WO 03/072553, WO 03/064415 disclose heterobicyclic substituted phenyl oxazolidinones useful as antibacterial agents.
- WO 96/35691 and WO 00/073301 disclose bicyclic oxazolidinones as antibacterial agents.
- WO 02/064547 discloses pyridoarylphenyl oxazolidinones as antibacterial agents.
- WO 04/033451, WO 04/089943, WO 05/005422 and WO 05/005399 disclose bicyclo[3.1.0]hexyl-phenyl-oxazolidinone derivatives useful for treating bacterial infections.
- Linezolid (sold under the trade name Zyvox ), the first oxazolidinone to receive regulatory approval, has become an important clinical option in the treatment of serious Gram-positive bacterial infections, including those caused by multidrug resistant pathogens such as MRSA and VRE (see WO 95/07272). Inspite of its high potential as an antibiotic and its unique mode of action, no other molecule from oxazolidinone class, except for linezolid, could make it to the clinic. Moreover, development of resistance to an antibiotic is inevitable, and linezolid has been no exception. See, Mutnick, A. H.; Enne, V.; Jones, R. N. Ann. Pharmacother., 2003, 37, 769-774.3.
- linezolid is not suitable for long duration therapy, although there are cases where patients receiving linezolid for more than two years are without serious side effects. See, Hutchinson, D. K. Expert Opin. Ther. Patents 2004, 14, 1309-1328.
- Linezolid and its analogs are generally limited in their antimicrobial spectrum to Gram-positive pathogens only.
- An expanded spectrum and enhanced potency of newer second generation oxazolidinones with activity against Gram-negative pathogens could expand the utility of this class beyond the hospital setting into the treatment of community acquired infections.
- the compounds of the present invention are novel, none of them having being previously reported in the prior art.
- the novel compounds of formula I according to the present invention possess improved efficacy particularly enhanced activity against bacterial infections, appreciable bioavailability, reduced associated side effects, good solubility and can be made into formulations with ease.
- the present invention relates to novel phenyl oxazolidinones of formula I,
- P represents phosphorus
- O represents oxygen
- N represents nitrogen
- R can be either R 1 X or R 2 ;
- X represents O, S, -NH, -NR 3 , -CH 2, -CHR 3 , -C(R 3 ) 2 or -(CH 2 ) m -X-
- R 3 represents hydrogen, Cu io alkyl, C 2-I o alkenyl, C 2-I o alkynyl, acyl, thioacyl, aryl, heteroaryl, heterocyclyl, heteroarylcarbonyl, Ci -6 alkoxycarbonyl, Ci -6 alkoxythiocarbonyl, C 3-6 cyclo- alkoxycarbonyl, C 2-6 alkenyloxycarbonyl, C 2-6 alkenyloxythiocarbonyl, C 2-6 alkenyl- carbonyl, aryloxycarbonyl, aryloxythiocarbonyl, heteroaryloxycarbonyl, heteroarylthiocarbonyl, heteroaryloxythiocarbonyl or carbonyl and its derivatives, each of which may be optionally substituted at
- R 1 represents hydrogen, C MO alkyl, C 3-2 o cycloalkyl, C 2- ⁇ o alkenyl, C 2- I 0 alkynyl, substituted or unsubstituted aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl, each of which may be optionally substituted at any available position by one or more substituents R a ;
- R 2 represents C MO alkyl, C 3-2 O cycloalkyl, C 2- ⁇ o alkenyl, C 2- io alkynyl, substituted or unsubstituted aryl, heteroaryl or heterocyclyl, each of which may be optionally substituted at any available position by one or more substituents R a ;
- Z represents halogen, azido, isothiocyanate, thioalcohol, aryl, nitro, cyano, heteroaryl, OR 3 , NHR 3 or N(R 3 ) 2 where R J is as previously defined, each of which may be optionally substituted at any available position by one or more substituents R a ;
- T, U, V and W are same or different and independently represent hydrogen or halogen
- Y represents O, S, -NH or -NR where R 3 is as previously defined;
- C 6 alkyl, -CH NOH, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2- C 6 alkynyl, C,-C 6 alkoxy, C 3 -
- R 4 and R 5 are independently selected from hydrogen, Ci-C 6 alkyl, C 3 -C 2 ocycloalkyl, C 3 - C 2 ocycloalkylalkyl, C 2 -C 6 alkenyl, C 2- C 6 alkynyl, C)-C 6 alkoxyCi-C 6 alkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl, optionally substituted with phenyl, -OH,
- Ci-C 6 alkyl or Ci-C 6 alkoxy are same or different and independently represent 1,2,3 or 4; m is 1,2,3 or 4.
- Another aspect of the invention provides the processes for the preparation of the novel compounds of formula I or their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof.
- a further aspect of the present invention provides pharmaceutical compositions, containing compounds of formula I or their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof in combination with one or more pharmaceutically acceptable carrier(s).
- Another aspect of the invention is to provide methods of using the compounds of formula I of the present invention or compositions comprising the compounds of formula I for the management such as prophylaxis, amelioration and/or treatment of disease(s)/ disorder(s) especially caused by microbial infections which comprises administering to a subject in need thereof the compounds of formula I or compositions comprising a pharmaceutically effective amount of the compounds of formula I.
- Yet another aspect of the invention is the use of the compounds of formula I as antimicrobial agents, effective against a number of aerobic and/or anaerobic Gram positive and/or Gram negative pathogens such as multi drug resistant Staphylococcus spp., Streptococcus spp., Enterococcus spp., Bactericides spp., Clostridia spp., H. influenza, Moraxella Spp., as well as acid-fast organisms such as Mycobacterium tuberculosis and the like.
- a number of aerobic and/or anaerobic Gram positive and/or Gram negative pathogens such as multi drug resistant Staphylococcus spp., Streptococcus spp., Enterococcus spp., Bactericides spp., Clostridia spp., H. influenza, Moraxella Spp., as well as acid-fast organisms such as Mycobacterium tuberculosis and the like.
- the present invention provides a method for treating Gram positive and/or Gram negative pathogens in a mammal by administering a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt.
- the present invention also encompasses prodrugs and active metabolites of the compounds of the formula I.
- the present invention relates to novel phenyl oxazolidinones of formula I,
- P represents phosphorus
- O represents oxygen
- N represents nitrogen
- R can be either R 1 X or R 2 ;
- X represents O, S, -NH, -NR 3 , -CH 2, -CHR 3 , -C(R 3 ) 2 or -(CH 2 ) m -X-
- R 3 represents hydrogen, C MO alkyl, C 2-I0 alkenyl, C 2-I0 alkynyl, acyl, thioacyl, aryl, heteroaryl, heterocyclyl, heteroarylcarbonyl, Ci -6 alkoxycarbonyl, Ci -6 alkoxythiocarbonyl, C 3-6 cyclo- alkoxycarbonyl, C 2-6 alkenyloxycarbonyl, C 2-6 alkenyloxythiocarbonyl, C 2-6 alkenyl- carbonyl, aryloxycarbonyl, aryloxythiocarbonyl, heteroaryloxycarbonyl, heteroarylthiocarbonyl, heteroaryloxythiocarbonyl or carbonyl and its derivatives, each of which may be optionally substituted at any available position by
- R 1 represents hydrogen, Ci -I0 alkyl, C 3-20 cycloalkyl, C 2- io alkenyl, C 2-I0 alkynyl, substituted or unsubstituted aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl, each of which may be optionally substituted at any available position by one or more substituents R a ;
- R 2 represents C M O alkyl, C 3-20 cycloalkyl, C 2- I 0 alkenyl, C 2- I 0 alkynyl, substituted or unsubstituted aryl, heteroaryl or heterocyclyl, each of which may be optionally substituted at any available position by one or more substituents R a ;
- Z represents halogen, azido, isothiocyanate, thioalcohol, aryl, nitro, cyano, heteroaryl, OR 3 , NHR 3 or N(R 3 ) 2 where R 3 is as previously defined, each of which may be optionally substituted at any available position by one or more substituents R a ;
- T, U, V and W are same or different and independently represent hydrogen or halogen
- Y represents O, S, -NH or -NR 3 where R 3 is as previously defined;
- Formula Ia wherein R , X, Y, T, U, V, W and Z are defined herein; or their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof.
- R 1 , X, Y, T, U, V, W and Z are defined herein; or their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof.
- the present invention provides a compound of formula I wherein Z represents OR 3 , NHR 3 , N(R 3 ) 2 or heteroaryl and R 3 is selected from hydrogen, substituted or unsubstituted alkyl, acyl, thioacyl, Ci -6 alkoxycarbonyl or Ci -6 alkoxythiocarbonyl.
- the present invention provides a compound of formula I wherein Z represents NHR 3 or heteroaryl and R J is selected from methoxycarbonyl methoxythiocarbonyl, acyl or thioacyl.
- the present invention provides a compound of formula I wherein heteroaryl represents triazolyl or isoxazolyl.
- the present invention provides a compound of formula I wherein the substituents on R 3 are selected from halogen, hydroxyl, amino, monoalkylamino, dialkylamino, cyano, nitro, alkoxy, aryl, heteroaryl, hydroxyaryl, pyridyl, hydroxyaalkyl, alkoxyaryl or carboxyl and its derivatives.
- the present invention provides a compound of formula I wherein U and V represent hydrogen and T and W independently represent hydrogen or fluorine.
- the present invention provides a compound of formula I wherein both n and n' are 2.
- the present invention provides a compound of formula I wherein Y represents O. In another embodiment, the present invention provides a compound of formula I wherein wherein X represents O, -NH or S.
- the present invention provides a compound of formula I wherein R 1 and R 2 are selected from aryl, Ci -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl or heteroaryl, each of which may be optionally substituted at any available position by one or more substituents R a .
- alkyl may be straight or branched with 1 to 10 carbon atoms. These groups may further be substituted with one or more substituents selected from but not limited to, for example, halogen, hydroxyl, oxo, carboxyl, carboxyalkyl, azido, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkynyl, acyl acyloxy, aryl, heterocyclyl and heteroaryl.
- cycloalkyl refers to cyclic alkyl groups constituting of 3 to 20 carbon atoms having a single cyclic ring or multiple condensed rings, for example, fused or spiro systems which may optionally contain one or more olefinic bonds, unless otherwise constrained by the definition.
- Such cycloalkyl groups include, by way of example, single ring structures, for example, cyclopropyl, cyclobutyl, cyclopentenyl, cyclohexyl, cyclooctyl, and the like, or multiple ring structures, for example, adamantyl, and bicyclo[2.2.1] heptane, or cyclic alkyl groups to which is fused an aryl group, for example, indane and the like.
- Cycloalkyl groups may further be substituted with one or more substituents selected from but not limited to, for example, halogen, hydroxyl, oxo, carboxy, carboxyalkyl, azido, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkynyl, acyl acyloxy, aryl, heterocyclyl, heteroaryl.
- substituents selected from but not limited to, for example, halogen, hydroxyl, oxo, carboxy, carboxyalkyl, azido, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkynyl, acyl acyloxy, aryl, heterocyclyl, heteroaryl.
- alkoxy denotes the group O-alkyl wherein alkyl is the same as defined above.
- aralkyl refers to alkyl-aryl linked through alkyl (wherein alkyl is the same as defined above) portion and the said alkyl portion contains carbon atoms from 1-6 and the aryl is as defined herein, after.
- the examples of aralkyl groups include benzyl and the like.
- aryl refers to a carbocyclic aromatic group, for example phenyl or naphthyl ring and the like optionally substituted with one or more substituents selected from but not limited to, for example, halogen, hydroxyl, alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, acyl, aryloxy, CF 3 , COOR d (wherein R d can be hydrogen, alkyl, alkenyl, cycloalkyl, aralkyl, heterocyclylalkyl or heteroarylalkyl), cyano, nitro, carboxy, heterocyclyl, heteroaryl, heterocyclylalkyl or heteroarylalkyl.
- the aryl group may optionally be fused with cycloalkyl group, wherein the said cycloalkyl group may optionally contain heteroatoms selected from O, N, S.
- aryloxy denotes the group O- aryl wherein aryl is as defined above.
- heteroaryl refers to an aromatic ring structure containing 5 to 8 carbon atoms, fully or partially unsaturated, or a bicyclic aromatic group having 8 to 10 carbon atoms with one or more heteroatom(s) independently selected from N, O and S and optionally substituted with 1 to 4 substituent(s) selected from but not limited to halogen, hydroxyl, alkyl, alkenyl, alkynyl, cycloalkyl, acyl, carboxy, aryl, alkoxy, aralkyl, cyano, nitro, heterocyclyl, or heteroaryl.
- heteroaryl groups include oxazolyl, imidazolyl, pyrrolyl, 1,2,3,-triazolyl, 1,2,4-triazolyl, tetrazolyl, thiazolyl, oxadiazolyl, benzoimidazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, thienyl, isoxazolyl, triazinyl, furanyl, benzofuranyl, indolyl, benzothiazolyl, benzoxazolyl, and the like.
- heterocyclyl refers to a non-aromatic monocyclic or bicyclic cycloalkyl group, fully or partially unsaturated having 5 to 10 carbon atoms, with one or more heteroatom(s) independently selected from N, O and S, and are optionally benzofiised or fused heteroaryl of 5-6 ring members and/or are optionally substituted wherein the substituents are selected from but not limited to halogen, hydroxyl, alkyl, alkenyl, alkynyl, cycloalkyl, acyl, carboxy, aryl, alkoxy, aralkyl, cyano, nitro, heterocyclyl, or heteroaryl.
- heterocyclyl groups include but are not limited to oxazolidinyl, tetrahydrofuranyl, dihydrofuranyl, dihydropyridinyl, dihydroisooxazolyl, dihydrobenzofuryl, azabicyclohexyl, dihydroindonyl, piperidinyl or piperazinyl.
- Heteroarylalkyl refers to alkyl-heteroaryl group linked through alkyl portion, wherein the alkyl and heteroalkyl are the same as defined previously.
- Heterocyclylalkyl refers to alkyl-heterocyclyl group linked through alkyl portion, wherein the alkyl and heterocyclyl are the same as defined previously.
- Halogen refers to Br, Cl, F or I.
- protecting group when the functional group is termed "protected", this means that the group is in modified form to preclude undesired side reactions at the protected site.
- protecting group may be used with groups, for example, hydroxyl, amino, carboxyl and examples of such groups are found in T. W. Greene, et al. "Protecting Groups in Organic Synthesis," 3 rd Ed, Wiley, New York, which is incorporated herein by reference.
- Suitable hydroxyl and amino protecting groups are: trimethylsilyl, triethylsilyl, ⁇ -nitrobenzyloxycarbonyl, /7-nitrobenzyloxycarbonyl, t-butyldiphenylsilyl, t- butyldimethylsilyl, benzyloxycarbonyl, /-butyloxycarbonyl, 2,2,2- trichloroethyloxycarbonyl, allyloxycarbonyl and the like.
- carboxyl protecting groups are benzhydryl, o-nitrobenzyl, /?-nitrobenzyl, 2-naphthylmethyl, allyl, 2- chloroallyl, benzyl, 2,2,2- trichloroethyl, trimethylsilyl, t-butyldimethylsilyl, t- butyldiphenylsilyl, 2-(trimethylsilyl)ethyl, phenacyl, /?-methoxybenzyl, acetonyl, p- methoxyphenyl, 4-pyridylmethyl, t-butyl and the like.
- Subject includes humans, non-human mammals (e.g., dogs, cats, rabbits, cattle, horses, sheep and the like) or non-mammals (e.g., birds and the like).
- non-human mammals e.g., dogs, cats, rabbits, cattle, horses, sheep and the like
- non-mammals e.g., birds and the like
- terapéuticaally effective amount means the amount of a compound that, when administered to a subject for treating a disease, is sufficient to effect such treatment for the disease.
- the “therapeutically effective amount” will vary depending on the compound, the disease and its severity, weight, physical condition and responsiveness of the subject to be treated, among other factors.
- the compounds provided herein may contain one or more asymmetric carbon atoms and thus can exist as racemates, mixtures of enantiomers, single enantiomers, diastereomeric mixtures and individual diastereomers. All such isomeric forms of these compounds are expressly encompassed herein.
- Each stereogenic carbon may be independently of the R or 5 configuration.
- the specific compounds exemplified in this application may be depicted in a particular stereochemical configuration, compounds having the opposite stereochemistry at the chiral centre or mixtures thereof are encompassed herein.
- Some compounds of the present invention may exhibit cis/trans isomers.
- the present invention includes each of the geometric isomers and its mixtures.
- particularly useful compounds of formula Ib include but are not limited to the following:
- the compounds of the present invention can be prepared in accordance with one or more of the Schemes discussed herein after. All of the starting materials are either commercially available or can be prepared by procedures that would be well known to one of ordinary skill in organic chemistry.
- L is used to denote an appropriate leaving group and as such may vary in nature depending on the exact reaction conditions employed. Some typical leaving groups may be fluoro, chloro, bromo, iodo, tosyl, mesyl, trifluoromethanesulfonyl and the like, but these should not be construed as limiting as many other leaving groups are also well known to those skilled in the art.
- the compound of formula IV can also be prepared following literature procedure Gouverneur et al, Tetrahedron 2005, 61, 2395.
- Compounds of Formula II or IV can be reacted with benzylamine or substituted benzylamine to form compounds of Formula V without any solvent or in a suitable solvent such as methanol, ethanol, isopropanol and the like or mixtures thereof.
- Compounds of Formula V can be then debenzylated to form compounds of Formula VI.
- This conversion can be accomplished by hydrogenation over an appropriate catalyst such as palladium, platinum, or ruthenium onactivated carbon in a suitable solvent such as methanol, ethanol, isopropanol and the like or by using 1-chloroethyl chloroformate, CAN, DDQ or by other chemical methods known to those skilled in art.
- Compounds of Formula VI can be treated with a substituted nitrobenzene derivatives of Formula VII (wherein T 5 U 5 V 5 W are the same as defined earlier and L is an appropriate leaving group such as fluoro, chloro, bromo, iodo) to form compounds of Formula VIII in an appropriate solvent and base.
- the reaction can be allowed to proceed at an appropriate temperature, which, depending on the solvent may be between 60 to 100 0 C until such time that the reaction is determined to be complete.
- appropriate solvents include acetonitrile, tetrahydrofuran, methylene dichloride or dichloroethane or other such solvents well known to those skilled in the art.
- appropriate bases include but are not limited to triethylamine or diisopropylethyl amine.
- nitro derivatives of Formula VIII can then be reduced to the corresponding amino compounds by a variety of reducing agents such as hydrogenation over an appropriate catalyst such as palladium, platinum, or ruthenium on activated charcoal or chemical methods such as reaction with FeCl 3 or SnCl 2 /HCl or FeZNH 4 Cl or NiCl 2 ZNaBH 4 familiar to those skilled in the art.
- reducing agents such as hydrogenation over an appropriate catalyst such as palladium, platinum, or ruthenium on activated charcoal or chemical methods such as reaction with FeCl 3 or SnCl 2 /HCl or FeZNH 4 Cl or NiCl 2 ZNaBH 4 familiar to those skilled in the art.
- the resulting amine can then be treated with benzyl or methyl chloroformate and sodium bicarbonate in presence of water and acetone to form the corresponding benzyl or methyl carbamate derivatives IX which are then deprotonated in the next step with a lithium base such as «-butyllithium and reacted with Glycidyl butyrate in presence of a suitable solvent such as diethylether or tetrahydrofuran to afford the oxazolidinone X.
- the hydroxyl group can be converted to an amine (that is where Z is amino group) by first conversion of hydroxyl group to a leaving group such as mesylate or tosylate followed by conversion to azide, and finally reduction to amine.
- the particular method chosen for this reduction can be readily selected by those skilled in the art and is dependent upon the structure of the entirety of the molecule.
- the hydroxyl group can be converted to Z (wherein Z is as defined earlier).
- the exact nature of the reagents used for this conversion is dependent on the exact nature of the Z desired. For example, if Z is desired to be acetylamine group, the hydroxyl group is first converted to amino group which is then acylated in the presence of suitable acylating reagents such as acetic anhydride, acetyl chloride or the like. If Z is desired to be carbamate group, the hydroxyl group is first converted to amino group which is then reacted with alkyl chloroformate or the like. If Z is desired to be heterocycle like triazole, hydroxy group is first converted to azide, followed by reaction with 2,5-Norbornadiene or the like.
- the hydroxyl group is first converted to the mesylate or other appropriate leaving group and then reacted with a suitable hydroxyl containing heterocycle in the presence of suitable base and solvent such as sodium hydride and N, N- dimethylformamide (DMF) or the like.
- suitable base and solvent such as sodium hydride and N, N- dimethylformamide (DMF) or the like.
- suitable base and solvent such as sodium hydride and N, N- dimethylformamide (DMF) or the like.
- suitable base and solvent such as sodium hydride and N, N- dimethylformamide (DMF) or the like.
- the compounds of Formula XXI can be converted into compounds of Formula XXIII, as shown in Scheme III.
- the compounds of Formula XXI can be converted into compounds of Formula XXII when R is OR 1 wherein R 1 is preferably ethyl or methyl, by deprotection of phosphate ester group to phosphinic acid in presence of a suitable deprotecting agent such as trimethylsilyl chloride, trimethylsilyl bromide and the like in a suitable solvent such as methylene chloride, dichloroethane, tetrahydrofuran, diethylcther, acetonitrile and the like or mixtures thereof.
- a suitable deprotecting agent such as trimethylsilyl chloride, trimethylsilyl bromide and the like
- a suitable solvent such as methylene chloride, dichloroethane, tetrahydrofuran, diethylcther, acetonitrile and the like or mixtures thereof.
- the compounds of Formula XXII can then be reacted with either alcohol (R 1 OH) or amine (R 1 NH 2 ) or substituted amine (R 1 NR 2 ) or thiol (R 1 SH), wherein R 1 and R 2 are as defined earlier, to form compounds of Formula XXIII in the presence of one of the following suitable reagents such as N,N'-Dicyclohexylcarbodiimide (DCC), 4- dimethylaminopyridine (DMAP); or l-Ethyl-3-[3-dimethyl aminopropyl] carbodiimide hydrochloride (EDC) in presence of Hydroxy benztriazole (HOBt) and N- methylmorphiline; or mixed anhydrides such as benzylchloro formate, ethylchloro formate or tertiary butyl chloro formate; or oxalyl chloride in presence of DMAP; or alkyl/aryl halide in the
- the suitable solvents required for this conversion include but are not limited to toluene, DMF, methylene chloride, dioxane, acetone, diethylether, tetrahydrofuran and the like.
- the particular reagents chosen for this conversion can be readily selected by those skilled in the art and is dependent upon the structure of the entirety of the molecule.
- the compound XVII can also be hydrolysed to hydroxyl compound when R is OR 1 , R 1 preferably ethyl or methyl and different R 1 can be introduced as explained above in conversion of XXI to XXII and finally to XXIII.
- the compounds of Formula XXIII can then be converted to compounds of Formula XXIV following the reaction with Lawsson's reagent or phosphorous pentasulphide in the presence of a suitable solvent such as toluene, benzene, xylene and the like or mixtures thereof.
- a suitable solvent such as toluene, benzene, xylene and the like or mixtures thereof.
- reaction can also be carried out jn the absence of base by reacting two substrates in seal tube (Hii et al, J. Org. Chem. 2006, 71, 2472).
- the particular method chosen for this conversion can be readily selected by those skilled in the art and is dependent upon the structure of the entirety of the molecule.
- Compounds of Formula XXV can then be debenzylated to form compounds of Formula XXVI as described in scheme II.
- the pharmaceutically acceptable salts of compounds of formula I according to the present invention include acid addition salts or base addition salts where appropriate.
- Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example, by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion.
- Alkali metal or alkaline earth metal salts of carboxylic acids can also be made.
- Pharmaceutically acceptable solvates may be hydrates or comprising other solvents of crystallization such as alcohols.
- prodrugs of the compounds of the present invention which upon in-vivo administration undergo chemical conversion by metabolic processes before becoming active pharmacological substances.
- prodrugs will be functional derivatives of a compound of the invention which are readily convertible in vivo into the compound of the invention.
- Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in “Targeted prodrug design to optimize drug delivery", AAPS PharmaSci (2000), 2(1), E6.
- the invention also encompasses active "metabolites" of the compound of the present invention.
- polymorphs For example, using different solvents commonly used or their mixtures for recrystallization; crystallizations at different temperatures; various modes of cooling, ranging from very fast to very slow cooling during crystallizations, heating or melting the compound followed by gradual or fast cooling may also obtain polymorphs.
- the presence of polymorphs may be determined by solid probe NMR spectroscopy, IR spectroscopy, differential scanning calorimetry, powder X-ray diffraction or such other techniques.
- the present invention also provides pharmaceutical compositions, comprising compounds of general formula I or their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof together with one or more pharmaceutically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active compound into preparations, which can be used pharmaceutically.
- the pharmaceutical compositions may be in the forms normally employed, such as tablets, capsules, powders, syrups, solutions, suspensions and the like, may contain flavourants, sweeteners etc in suitable solid or liquid carriers or diluents, or in suitable sterile media to form injectable solutions or suspensions.
- compositions typically contain from 0.1 to 99.9 % by weight of active compound, the remainder of the composition being pharmaceutically acceptable carriers, diluents or solvents.
- the pharmaceutical compositions of the present invention can be manufactured by the processes well known in the art, for example, by means of conventional mixing, dissolving, dry granulation, wet granulation, dragee-making, levigating, emulsifying, encapsulating, entrapping, lyophilizing processes or spray drying.
- the compounds or the pharmaceutical compositions comprising such compounds of the present invention may be administered in the form of any pharmaceutical formulation.
- the pharmaceutical formulation will depend upon the nature of the active compound and its route of administration.
- any route of administration may be used, for example oral, buccal, pulmonary, topical, parenteral (including subcutaneous, intramuscular and intravenous), transdermal, ocular (ophthalmic), by inhalation, intranasal, transmucosal, implant or rectal administration.
- parenteral including subcutaneous, intramuscular and intravenous
- transdermal ocular
- ocular ophthalmic
- the compounds of the present invention are administered orally, parenterally or topically.
- the amount of the novel compounds having the formula I according to the present invention to be incorporated into the pharmaceutical compositions of the present invention can vary over a wide range depending on known factors such as, for example, the disorder to be treated, the severity of the disorder, the patient's body weight, the dosage form, the chosen route of administration and the number of administration per day.
- the amount of the compound of formula I in the pharmaceutical compositions of the present invention will range from approximately 0.01 mg to about 5000 mg.
- the daily dose of composition comprising the novel compounds having the formula-I is in the range of about 0.01 mg/kg to about 100 mg/kg based on the body weight of the subject in need thereof which may be administered as a single or multiple doses.
- novel compounds having the formula I according to the present invention are particularly useful for the treatment of disease(s) or disorder(s) which are particularly acute in nature and which require a short term but mild to moderate treatment, or even some chronic conditions which favorably respond to or are alleviated by the novel compounds having the formula-I or compositions comprising them.
- the compositions comprising the novel compounds having the formula-I are useful prophylactically or therapeutically depending upon the pathological condition intended to be prevented or treated respectively.
- the compounds of the present invention are effective against a number of aerobic and/or anaerobic Gram positive and/or Gram negative pathogens such as multi drug resistant Staphylococcus spp., Streptococcus spp., Enterococcus spp., Bacterioides spp., Clostridia spp., H. influenza, Moraxella Spp., as well as acid-fast organisms such as Mycobacterium tuberculosis and the like.
- a further embodiment of the present invention is the use of a compound of formula I for the manufacture of a medicament for the prophylaxis, amelioration and/or treatment of bacterial infections in a subject in need thereof preferably a mammal including a human.
- Another embodiment of the present invention provides methods for the management such as prophylaxis, amelioration and/or treatment of bacterial infections in a subject in need thereof preferably a mammal including a human that comprises administering a therapeutically effective amount of compound of formula I.
- use of the dosage form compositions comprising the novel compounds of formula I for the treatment of diseases/disorders which comprises administrating to a subject in need thereof a pharmaceutically effective amount of the composition.
- the compounds of the present invention may be used in combination with one or more other active ingredients such as quinolines, ⁇ -lactams e.g., cephalosporins, penicillins, penams, penems and the like in the prophylaxis, amelioration and/or treatment of bacterial infections, where the combination of the active ingredients together are safer or more effective than either active ingredient alone or where incorporation of another active ingredient might reduce the dose of the compound of formula I.
- active ingredients such as quinolines, ⁇ -lactams e.g., cephalosporins, penicillins, penams, penems and the like in the prophylaxis, amelioration and/or treatment of bacterial infections, where the combination of the active ingredients together are safer or more effective than either active ingredient alone or where incorporation of another active ingredient might reduce the dose of the compound of formula I.
- MS mass spectra
- Step 3 Preparation of 4-ethoxy-l-(2-fluoro-4-nitro-phenyl)-[l,4]azaphosphinane-4- oxide
- 4-ethoxy-[l,4]azaphosphinane 4-oxide (2.3 g, 14.1 mmol) in acetonitrile (10 mL) was added diisopropylethylamine (3.7 mL, 21.15 mmol) and 3,4-difluoronitrobenzene (1.87 mL, 16.92 mmol).
- the reaction mixture was refluxed at 80 °C for 24 h.
- Step 4 Preparation of 4-(4-ethoxy-4-oxo-4 ⁇ 5 -[l,4]azaphosphinan-l-y.)-3-fluoro- phenyl-amine
- Step 6 Preparation of fl?,)-3-[4-(4-ethoxy-4-oxo-4 ⁇ 5 -[l,4]azaphosphinan-l-yl)-3-fluoro- pheny] -S-hydroxylmethyl-oxazolidin-2-one
- Step 9 Preparation of (S)-iV- ⁇ 3-[4-(4-ethoxy-4-oxo-4 ⁇ 5 -[l,4]azaphophinan-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5ylmethyI ⁇ -acetamide
- To (7?)-5-Azidomethyl-3-[4-(4-ethoxy-4-oxo-4 ⁇ 5 -[ 1 ,4]aza ⁇ hosphinan- 1 -yl)-3-fluoro-phen- yl-oxazolidin-2-one (415 mg, 1.045 mmol) was added thioacetic acid (2.7 mL) and stirring was done at room temperature for 15 h.
- Reaction mixture was refluxed at 120 0 C for 15 min followed by addition of cyclopentylmethanol (0.04 mL, 0.372 mmol) and refluxing was done for 7 h. Solvent was evaporated and reaction mixture was diluted with dichloromethane (20 mL). Organic layer was washed with 10% HCl then with saturated NaHCO 3 followed by washing with water and brine. The organic layer was dried over anhydrous sodium sulfate and the crude product was then purified by column chromatography using 4% methanol in chloroform to yield the title compound (40 mg, 26.6 %).
- reaction mixture was refluxed at 120 0 C for 15 min followed by addition of phenol (77 mg, 0.819 mmol) and refluxing was done for 5 h. Solvent was evaporated and reaction mixture was diluted with dichloromethane (20 mL). Organic layer was washed with 10% HCl then with saturated NaHCO 3 . The organic layer was then washed with water and brine, dried over anhydrous sodium sulfate and evaporated to yield the crude product which was then purified by column chromatography using 4% methanol in chloroform to yield the title compound (250 mg, 70 %).
- Reaction mixture was refluxed at 120 0 C for 15 min followed by addition of benzylamine (0.07 mL, 0.595 mmol) and refluxing was done for 4 h. Solvent was evaporated and reaction mixture was diluted with dichloromethane (20 mL). The organic layer was washed with water and brine, dried over anhydrous sodium sulfate and evaporated to yield the crude product which was then purified by column chromatography using 4% methanol in chloroform to yield the title compound (25mg, 10.2 %).
- Step 2 Preparation of (S)- ⁇ 3-[4-(4-ethoxy-4-oxo-4 ⁇ 5 -[l,4]azaphosphinan-l-yl)-3,5- difluoro-phenyI]-2-oxo-oxazoIidin-5-ylmethyl ⁇ -carbamic acid methyl ester
- reaction mixture was diluted with dichloromethane (30 mL). Organic layer was washed with water and brine and then dried over anhydrous sodium sulfate. Solvent was concentrated and crude product was purified by column chromatography using 2 % methanol in chloroform to yield the title compound (150 mg, 56.5 %).
- Step 1 Preparation of ⁇ 3-[3,5-Difluoro-4-(4-hydroxy-4-oxo-4 ⁇ -[l,4]azaphosphinan-l- yl)-phenyI]-2-oxo-oxazolidi ⁇ -5-ylmethyl ⁇ -carbamic acid methyl ester
- ⁇ 3-[4-(4-Ethoxy-4-oxo-4 ⁇ 3 -[l,4]azaphosphinan-l-yl)-3,5-difluoro- phenyl]-2-oxo-oxazolidin-5-ylmethyl ⁇ -carbamic acid methyl ester (given in example XV ) (2 g, 4.47 mmol) in dichloromethane bromotrimethylsilane (0.88 mL, 6.71 mmol) was added and dichloromethane was refluxed for overnight.
- Step 2 Preparation of (S)-(3- ⁇ 3,5-Difluoro-4-[4-(4-methoxy-phenoxy)-4-oxo-4 ⁇ 5 -
- reaction mixture was refluxed at 120 0 C for 15 min followed by addition of 4-methoxyphenol (65 mg, 0.52 mmol) and refluxing was done for 16 h. Solvent was evaporated and reaction mixture was diluted with dichloromethane (20 mL). Organic layer was washed with 10% HCl then with saturated NaHCO 3 . The organic layer was then washed with water and brine, dried over anhydrous sodium sulfate and evaporated to yield the crude product which was then purified by column chromatography using 3% methanol in chloroform to yield the title compound (130 mg, 51.9 %).
- reaction mixture was refluxed at 120 0 C for 15 min followed by addition of 4-fluorophenol (26.7 mg, 0.23 mmol) and refluxing was done for 5 h. Solvent was evaporated and reaction mixture was diluted with dichloromethane (20 mL). Organic layer was washed with 10% HCl then with saturated NaHCO 3 . The organic layer was then washed with water and brine, dried over anhydrous sodium sulfate and evaporated to yield the crude product which was then purified by column chromatography using 4% methanol in chloroform to yield the title compound (20 mg, 18.18 %).
- Analogues of direct phenyl compounds were prepared by taking (Divinyl-phosphinoyl)- benzene instead of divinylphosphinic acid ethyl ester in step 1 in Example I. Rest all the steps were done as in Example 1.
- Step 1 Preparation of l-Benzyl-4-phenyl-[l,4]azaphosphinane 4-oxide ESIMS (m/z): 287.1 (M+2), 286.2 (M+l), 201.0, 179.1
- Step 2 Preparation of 4-Phenyl-[l,4]azaphosphinane 4-oxide ESIMS (m/z): 218.0 (M+Na), 196.4 (M+l), 183.2
- Step 3 Preparation of l-(2,6-Difluoro-4-nitro-phenyI)-4-phenyl-[l,4]azaphosph-inane
- Step 4 Preparation of 3,5-Difluoro-4-(4-oxo-4-phenyl-4 ⁇ 5 -[l,4]azaphosphinan-l-yl)- phenylamine
- Step 5 Preparation of [3,5-Difluoro-4-(4-oxo-4-phe ⁇ yl-4 ⁇ 5 -[l,4]azaphosphi ⁇ an-l-y.)- phenylj-carbamic acid benzyl ester
- Step 7 Preparation of Methanesulfonic acid 3-[3,5-difluoro-4-(4-oxo-4-phenyl-4 ⁇ 5 -
- Step 8 Preparation of 5-Azidomethyl-3-[3,5-difluoro-4-(4-oxo-4-phenyI-4 ⁇ 5 -
- Step 9 Preparation of (£)- ⁇ r - ⁇ 3-[3,5-Difluoro-4-(4-oxo-4-phenyl-4 ⁇ 5 -[l,4]azapho- sphinan-l-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl ⁇ -acetamide
- This compound was prepared by taking 5-Azidomethyl-3-[3,5-difluoro-4-(4-oxo-4-phenyl- 4 ⁇ 5 -[l,4]azaphosphinan-l-yl)-phenyl]-oxazolidin-2-one instead of (7?)-5-azidomethyl3-[4-
- Step 1 Preparation of 5-Aminomethyl-3-[3,5-difluoro-4-(4-oxo-4-phenyI-4 ⁇ 5 -
- Step 2 Preparation of 4-(4-Fluoro-phenyl)-l-(4-methoxy-benzyl)-[l,4]azaphosphin- ane 4-oxide
- Step 3 Preparation of 4-(4-fluoro-phenyl)-[l,4]azaphosphinane 4-oxide ESIMS (m/z): 236.2 (M+Na), 214.1 (M+l)
- Step 4 Preparation of l-(2,6-Difluoro-4-nitro-phenyl)-4(4-Fluoro-phenyl)-[l,4]aza- phosphinane 4-oxide
- Step 5 Preparation of 3,5-Difluoro-4[4-(4-fluoro-phenyl)-4-oxo-4 ⁇ 5 -[l,4]azaphos- phinan-l-yl]-phenylamine
- Step 6 Preparation of ⁇ 3,5-Difluoro-4-[4-(4-fluoro-phenyl)-4-oxo-4 ⁇ ' -[l,4]azaphos- phinan-l-yi]-phenyl ⁇ -carbamic acid benzyl ester
- Step 8 Preparation of Methanesulfonic acid 3- ⁇ 3,5-difluoro-4-[4-(4-fluoro-phenyI)-4- oxo-4 ⁇ 5 -[l,4]azaphosphinan-l-yl]-phenyl ⁇ -2-oxo-oxazolidin-5-ylmethyl ester ESIMS (m/z): 542.2 (M+Na+1), 541.3 (M+Na), 519.1 (M+l)
- Step 9 Preparation of (S)-iV-(3- ⁇ 3,5-Difluoro-4-[4-(4-fluoro-pheny])-4-oxo-4 ⁇ 5 -
- Step 1 Preparation of 5-AzidomethyI-3- ⁇ 3,5-difluoro-4-[4-(4-fluoro-phenyl)-4-oxo-
- Step 2 Preparation of 5-AminomethyI-3- ⁇ 3,5-difluoro-4-[4-(4-fluoro-phenyl)-4-oxo- 4 ⁇ -[l,4]azaphosphinan-l-yl]-phenyl ⁇ -oxazolidin-2-one
- Step 3 Preparation of (3- ⁇ 3,5-Difluoro-4-[4-(4-fluoro-phenyl)-4-oxo-4 ⁇ s -
- MIC Minimum Inhibitory Concentration
- the compounds of the present invention were tested against a panel of standard microorganisms obtained from ATCC (American type culture collection). Linezolid was used as comparator in all the tests.
- the compound was dissolved in dimethylsulfoxide and two fold serial dilutions were carried out in 96 well microtitre plates.
- the inoculum was prepared by adjusting the turbidity of actively growing broth culture and added to the wells to obtain a final concentration of approx. 5x10 4 CFU/well.
- the microtitre plates were incubated at 35 ⁇ 2°C for 16-20 hrs and then read visually.
- MIC S ( ⁇ g/mL) of some of the compounds of formula 1 are presented in the Table 1.
- the compounds of the present invention show potential antibacterial activity against Staphylococcus aureus (MRSA) and Enterococci (VRE).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La présente invention porte sur de nouveaux composés de phényl oxazolidinone de formule (I) ou sur leurs analogues, formes tautomères, stéréo-isomères, polymorphes, promédicaments, métabolites, sels ou solvates pharmaceutiquement acceptables de ceux-ci. L'invention porte également sur les procédés pour la synthèse des nouveaux composés de formule (I) ou sur leurs analogues, formes tautomères, stéréo-isomères, polymorphes, promédicaments, métabolites, sels ou solvates pharmaceutiquement acceptables de ceux-ci. La présente invention porte aussi sur des compositions pharmaceutiques comprenant de nouveaux composés de formule (I) et sur des procédés d'utilisation de ceux-ci. Les composés de la présente invention sont utiles comme agents antimicrobiens, efficaces contre un nombre de pathogènes Gram positif et/ou Gram négatif aérobies ou anaérobies, tels que des Staphylococcus spp., Streptococcus spp., Enterococcus spp., Bacterioides spp., Clostridia spp., H. influenza, Moraxella Spp., multirésistants aux médicaments, ainsi que des organismes résistants aux acides tels que Mycobacterium tuberculosis et similaires.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN167/DEL/2007 | 2007-01-25 | ||
IN167DE2007 | 2007-01-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008090570A1 true WO2008090570A1 (fr) | 2008-07-31 |
Family
ID=39644167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2008/000047 WO2008090570A1 (fr) | 2007-01-25 | 2008-01-24 | Nouveaux antimicrobiens |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008090570A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011070592A2 (fr) | 2009-12-09 | 2011-06-16 | Panacea Biotec Ltd. | Nouveaux dérivés de sucres |
CN105820161A (zh) * | 2015-01-08 | 2016-08-03 | 常州方楠医药技术有限公司 | 一种利伐沙班中间体5-羟基甲基噁唑烷酮衍生物的合成方法 |
WO2021014365A1 (fr) | 2019-07-22 | 2021-01-28 | Lupin Limited | Composés macrocycliques utilisés en tant qu'agonistes sting et procédés et utilisations de ceux-ci |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002002095A2 (fr) * | 2000-06-30 | 2002-01-10 | Pharmacia & Upjohn Company | Composition et techniques de traitement d'infections bacteriennes |
WO2003093247A2 (fr) * | 2002-04-30 | 2003-11-13 | Orchid Chemicals & Pharmaceuticals Ltd | Nouveaux agents antibacteriens |
-
2008
- 2008-01-24 WO PCT/IN2008/000047 patent/WO2008090570A1/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002002095A2 (fr) * | 2000-06-30 | 2002-01-10 | Pharmacia & Upjohn Company | Composition et techniques de traitement d'infections bacteriennes |
WO2003093247A2 (fr) * | 2002-04-30 | 2003-11-13 | Orchid Chemicals & Pharmaceuticals Ltd | Nouveaux agents antibacteriens |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011070592A2 (fr) | 2009-12-09 | 2011-06-16 | Panacea Biotec Ltd. | Nouveaux dérivés de sucres |
CN105820161A (zh) * | 2015-01-08 | 2016-08-03 | 常州方楠医药技术有限公司 | 一种利伐沙班中间体5-羟基甲基噁唑烷酮衍生物的合成方法 |
WO2021014365A1 (fr) | 2019-07-22 | 2021-01-28 | Lupin Limited | Composés macrocycliques utilisés en tant qu'agonistes sting et procédés et utilisations de ceux-ci |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100312903B1 (ko) | 치환된-하이드록시아세틸피페라진페닐옥사졸리디논의에스테르 | |
DE60205030T2 (de) | Oxazolidinon- und/oder isoxazolinderivate als antibakterielle mittel | |
DE602004004808T2 (de) | Acyloxymethylcarbamatoxazolidinone und ihre Präparationen | |
KR20020067557A (ko) | 설폭시민 관능기를 가지는 옥사졸리디논 및항미생물제로서의 그의 용도 | |
WO1997027188A1 (fr) | Derives de piperazinonephenyloxazolidinone et leur utilisation en tant qu'agents antibacteriens | |
US20080090884A1 (en) | Antimicrobial [3.1.0] bicyclohexylphenyl- oxazolidinone derivatives and analogues | |
WO2012114355A1 (fr) | Nouveau procédé de préparation de linézolide et ses nouveaux intermédiaires | |
US8841306B2 (en) | Antimicrobials | |
US6686363B2 (en) | Cyclopropyl containing oxazolidinone antibiotics and derivatives thereof | |
US6281210B1 (en) | Benzoic acid esters of oxazolidinones having a hydroxyacetylpiperazine substituent | |
JP2007521283A (ja) | シクロプロピル基で置換されたオキサゾリジノン系抗生物質およびその誘導体 | |
WO2008090570A1 (fr) | Nouveaux antimicrobiens | |
US7592335B2 (en) | Oxazolidinone derivatives as antimicrobials | |
WO2009116090A2 (fr) | Nouveaux antimicrobiens | |
JP2007521284A (ja) | オキサゾリジノン系抗生物質及びその誘導体 | |
WO2006051408A1 (fr) | Derives d'oxazolidinone comme antimicrobiens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08702739 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08702739 Country of ref document: EP Kind code of ref document: A1 |